Cargando…

Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action

Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Kenneth H., Grinsztejn, Beatriz, El-Sadr, Wafaa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969053/
https://www.ncbi.nlm.nih.gov/pubmed/27429184
http://dx.doi.org/10.1097/QAI.0000000000001086
_version_ 1782445736492793856
author Mayer, Kenneth H.
Grinsztejn, Beatriz
El-Sadr, Wafaa M.
author_facet Mayer, Kenneth H.
Grinsztejn, Beatriz
El-Sadr, Wafaa M.
author_sort Mayer, Kenneth H.
collection PubMed
description Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of having HIV-infected partners), structural (eg, social stigma limiting employment options), and individual factors (eg, internalized stigma leading to depression and substance use and risk-taking behaviors). There have been limited culturally appropriate HIV prevention interventions for transgender people, with many key prevention studies (eg, the iPrEx PrEP study) enrolling transgender women in a study focusing on men who have sex with men. This has resulted in limited understanding of the optimal ways to decrease transgender people's risk for HIV acquisition. The current supplement of JAIDS is designed to review what is known about HIV prevention for transgender people and to highlight new insights and best practices. The study reviews recent epidemiologic data, the pharmacology of HIV prophylactic agents in individuals who may be using exogenous hormones, and several recent multi-component interventions designed to address the lived experience of transgender people. Additionally, the study reviews the work going on at the NIH to address transgender health in general and HIV prevention in specific, as well as two important papers related to clinical trial design issues and the ethical conduct of research in this frequently disenfranchised population. It is the hope of the HIV Prevention Trials Network (HPTN) that this supplement will promote new knowledge around transgender health and the requisite issues that need to be addressed in order to conduct optimal clinical trials. The ultimate hope is that the information distilled in this supplement will inform investigators, clinicians, and public health officials in order to design further research to develop optimal prevention interventions for transgender people and to implement these interventions in ways that are culturally congruent and health promoting.
format Online
Article
Text
id pubmed-4969053
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-49690532016-08-17 Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action Mayer, Kenneth H. Grinsztejn, Beatriz El-Sadr, Wafaa M. J Acquir Immune Defic Syndr Supplement Article Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of having HIV-infected partners), structural (eg, social stigma limiting employment options), and individual factors (eg, internalized stigma leading to depression and substance use and risk-taking behaviors). There have been limited culturally appropriate HIV prevention interventions for transgender people, with many key prevention studies (eg, the iPrEx PrEP study) enrolling transgender women in a study focusing on men who have sex with men. This has resulted in limited understanding of the optimal ways to decrease transgender people's risk for HIV acquisition. The current supplement of JAIDS is designed to review what is known about HIV prevention for transgender people and to highlight new insights and best practices. The study reviews recent epidemiologic data, the pharmacology of HIV prophylactic agents in individuals who may be using exogenous hormones, and several recent multi-component interventions designed to address the lived experience of transgender people. Additionally, the study reviews the work going on at the NIH to address transgender health in general and HIV prevention in specific, as well as two important papers related to clinical trial design issues and the ethical conduct of research in this frequently disenfranchised population. It is the hope of the HIV Prevention Trials Network (HPTN) that this supplement will promote new knowledge around transgender health and the requisite issues that need to be addressed in order to conduct optimal clinical trials. The ultimate hope is that the information distilled in this supplement will inform investigators, clinicians, and public health officials in order to design further research to develop optimal prevention interventions for transgender people and to implement these interventions in ways that are culturally congruent and health promoting. JAIDS Journal of Acquired Immune Deficiency Syndromes 2016-08-15 2016-07-18 /pmc/articles/PMC4969053/ /pubmed/27429184 http://dx.doi.org/10.1097/QAI.0000000000001086 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Supplement Article
Mayer, Kenneth H.
Grinsztejn, Beatriz
El-Sadr, Wafaa M.
Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title_full Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title_fullStr Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title_full_unstemmed Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title_short Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
title_sort transgender people and hiv prevention: what we know and what we need to know, a call to action
topic Supplement Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969053/
https://www.ncbi.nlm.nih.gov/pubmed/27429184
http://dx.doi.org/10.1097/QAI.0000000000001086
work_keys_str_mv AT mayerkennethh transgenderpeopleandhivpreventionwhatweknowandwhatweneedtoknowacalltoaction
AT grinsztejnbeatriz transgenderpeopleandhivpreventionwhatweknowandwhatweneedtoknowacalltoaction
AT elsadrwafaam transgenderpeopleandhivpreventionwhatweknowandwhatweneedtoknowacalltoaction